01_diamond_novaccel.png

NovAccel

02_platinum_ge_healthcare.png

GE Healthcare

02_platinum_siemens_healthineers.png

Siemens Healthineers

03_gold_triskem.png

TrisKem International

03_gold_comecer.png

Comecer

03_gold_shi.jpg

Sumitomo Heavy Industries

03_gold_isoflex.png

Isoflex USA

03_gold_iba.png

IBA RadioPharma Solutions

04_silver_vongahlen.png

Von Gahlen

04_silver_lablogic.png

LabLogic

04_silver_micromatter.jpg

Micromatter

04_silver_acsi.png

ACSI

04_silver_rqs.png

04_silver_xodus.png

Xodus Imaging

04_silver_acf.jpg

The Arizona Carbon Foil Co.

I.M.A. Industria Macchine Automatiche S.p.A.

04_silver_ima.png

04_silver_mtc.png

Metal Technology Co. Ltd.

04_silver_eichrom.jpg

Eichrom Technologies

04_silver_artms.png

ARTMS

05_gemstone_isoflex.png

05_gemstone_chiyoda_technol.png

Chiyoda Technol Corporation

05_gemstone_universal_giken.png

Universal Giken Co. Ltd.

General information

Announcements(0)

Timetable

Mon. Aug 24, 2026

Tue. Aug 25, 2026

Wed. Aug 26, 2026

Thu. Aug 27, 2026

Program

Sessions

Search presentations

Download PDF for print

web_header.png

web_icon.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

Program Type

Announcements

Profile management

Bookmark

Bremsstrahlung photon irradiation of [226Ra]RaCl2 (radium chloride) targets to produce no-carrier-added (n.c.a.) [225Ac]AcCl3 (actinium chloride) suitable for use as an active pharmaceutical ingredient (API)

Advances in Targeted Alpha Therapy: Development of Ra-226 Targets for Ac-225 Production at TRIUMF

Actinium Production

WTTC20

Session Details

[S9]Actinium Production

[S9-01]Bremsstrahlung photon irradiation of [²²⁶Ra]RaCl₂ (radium chloride) targets to produce no-carrier-added (n.c.a.) [²²⁵Ac]AcCl₃ (actinium chloride) suitable for use as an active pharmaceutical ingredient (API)

[S9-02]Advances in Targeted Alpha Therapy: Development of Ra-226 Targets for Ac-225 Production at TRIUMF

Session Details

[S9]Actinium Production

[S9-01]Bremsstrahlung photon irradiation of [226Ra]RaCl2 (radium chloride) targets to produce no-carrier-added (n.c.a.) [225Ac]AcCl3 (actinium chloride) suitable for use as an active pharmaceutical ingredient (API)

[S9-02]Advances in Targeted Alpha Therapy: Development of Ra-226 Targets for Ac-225 Production at TRIUMF

[S9-01]Bremsstrahlung photon irradiation of [²²⁶Ra]RaCl₂ (radium chloride) targets to produce no-carrier-added (n.c.a.) [²²⁵Ac]AcCl₃ (actinium chloride) suitable for use as an active pharmaceutical ingredient (API)